2235419-62-0
2235419-62-0
Chemical Structure
Lulizumab
Synonym(s): BMS-931699 Antibody
- CAS 番号: 2235419-62-0
- Formula:N/A
- Molecular Weight:(12.01 kDa)
IUPAC Name: dimethyl heptanedioate-2,2,6,6-d4
SMILES: [Lulizumab]
Biological Activity: Lulizumab (Humanized Anti-CD28 Recombinant Antibody) is an anti-CD28 domain antibody antagonist. Lulizumab inhibits T-cell activation by selectively targeting the CD28 signal. In a sensitized non-human primate kidney transplantation model, when combined with Carfilzomib (HY-10455), Lulizumab can regulate immune cells and prolong the survival time of the graft[1][2].
| 製品番号 | 製品名 | 純度 | 製品説明 | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Lulizumab | ≥95.0% | Lulizumab (Humanized Anti-CD28 Recombinant Antibody) is an anti-CD28 domain antibody antagonist. Lulizumab inhibits T-cell activation by selectively targeting the CD28 signal. In a sensitized non-human primate kidney transplantation model, when combined with Carfilzomib (HY-10455), Lulizumab can regulate immune cells and prolong the survival time of the graft. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Fernandes JC. Therapeutic application of antibody fragments in autoimmune diseases: current state and prospects. Drug Discov Today. 2018 Dec;23(12):1996-2002. [Content Brief]
- [2]. Schroder PM, et al. Preoperative carfilzomib and lulizumab based desensitization prolongs graft survival in a sensitized non-human primate model. Kidney Int. 2021 Jan;99(1):161-172. [Content Brief]
Keywords
